Rigel Pharmaceuticals acquires U.S. rights to Gavreto (pralsetinib) from Blueprint Medicines Corporation
Rigel Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to acquire the U.S. rights to Gavreto (pralsetinib) from Blueprint Medicines Corporation. Gavreto is a once… read more.
